CapitalBio, Population Genetics Technologies, Illumina, Nanogen, Gen-Probe, BioArray Solutions, Fluidigm
Christian Henry, Howard Birndorf, David Schreiber, Robert Whalen, Stelio Papadopoulos, Heiner Dreismann, Graham Lidgard, David Ludvigson, Nicholas Venuto, John Sweeney, Joan Wilson
The company said in a filing with the US Securities and Exchange Commission that the sale was closed following the completion of an auction process supervised by the court "in which Elitech emerged as the winning bidder."
The transfer to the Pink Sheets was expected after Nanogen received a delisting notice that it did not intend to appeal.
The firm has not paid certain outstanding fees as required for continued listing on the Nasdaq, and it also is in default of a financing agreement with GE.
Nanogen's full-year revenues rose 23 percent, but the firm's cash holdings has fallen to nearly $3 million, which is not enough funding to support its plans for 2009.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.